Compare PWP & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWP | DBVT |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2014 |
| Metric | PWP | DBVT |
|---|---|---|
| Price | $18.70 | $22.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $24.50 | ★ $31.75 |
| AVG Volume (30 Days) | ★ 969.4K | 245.6K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ 138.52 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $4,151,000.00 |
| Revenue This Year | $31.87 | $1,768.71 |
| Revenue Next Year | $17.25 | $1,028.88 |
| P/E Ratio | $39.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.44 | $3.91 |
| 52 Week High | $25.93 | $26.19 |
| Indicator | PWP | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 52.56 |
| Support Level | $18.66 | $20.11 |
| Resistance Level | $19.49 | $25.52 |
| Average True Range (ATR) | 1.02 | 1.33 |
| MACD | -0.40 | -0.04 |
| Stochastic Oscillator | 16.28 | 60.54 |
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.